Patients seeking GLP-1 therapy should consult healthcare providers about FDA-approved options
GLP-1R agonists represents a novel class of anti-hyperglycemic agent that improve health and survival of -cells (improvement in postprandial hyperglycemia), suppress glucagon (improvement in fasting hyperglycemia), improve insulin resistance (modest effect) and influence energy intake (augment satiety signal) with minimal, if at all, any side effects (weight neutral and non-hypoglycemic)
Even if you disagree with the clinical evidence above, the strongest prima facie evidence is that there are millions of people who: Want this treatment based on their understanding of the benefits & risks Are eligible for on-label treatment of this drug based on FDA approval Have healthcare providers who have determined it would be safe and appropriate for them to receive treatment Healthcare provider demand for their patients is in the millions
Byetta is administered twice daily
A large real-world study published in 2026 in the journal Inflammatory Bowel Diseases found that GLP-1 use in people with UC and Crohns disease was linked to lower rates of steroid use, hospitalization, and intestinal surgery
When feeling faint, sitting or lying down immediately prevents falls and injury
